RecruitingPhase 2NCT06527222

A Study of Ranolazine in ALS

Ranolazine in ALS: Safety, and Effect on Cramps, Function and Quality of Life.

Sponsor

Swathy Chandrashekhar, MBBS

Enrollment

72 participants

Start Date

Apr 29, 2025

Study Type

INTERVENTIONAL

Conditions

Amyotrophic Lateral Sclerosis

Summary

The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo, a drug called Ranolazine, and others for people with amyotrophic lateral sclerosis. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRanolazine

500mg twice daily

DRUGRanolazine

1000 mg twice daily

DRUGPlacebo

Ranolazine placebo twice daily

Locations(6)

University of California, San Francisco

San Francisco, California, United States

Mayo Clinic Florida

Jacksonville, Florida, United States

University of Kansas Medical Center

Fairway, Kansas, United States

University of Kansas Medical Center: Wichita

Wichita, Kansas, United States

University of Missouri Health Care

Columbia, Missouri, United States

The Ohio State University

Columbus, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06527222

Related Trials

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

NCT032251441 location

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT072900625 locations